Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Net Margin (2020 - 2025)

Historic Net Margin for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Q3 2025 value amounting to 21.24%.

  • Harmony Biosciences Holdings' Net Margin fell 35300.0% to 21.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.09%, marking a year-over-year increase of 30700.0%. This contributed to the annual value of 16.44% for FY2024, which is 57000.0% down from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Net Margin stood at 21.24% for Q3 2025, which was down 35300.0% from 19.84% recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Net Margin registered a high of 75.03% during Q3 2022, and its lowest value of 11.92% during Q3 2021.
  • Moreover, its 5-year median value for Net Margin was 24.0% (2023), whereas its average is 22.07%.
  • As far as peak fluctuations go, Harmony Biosciences Holdings' Net Margin soared by 2596800bps in 2021, and later crashed by -510300bps in 2023.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' Net Margin stood at 24.9% in 2021, then soared by 52bps to 37.81% in 2022, then tumbled by -79bps to 7.83% in 2023, then skyrocketed by 36bps to 10.67% in 2024, then skyrocketed by 99bps to 21.24% in 2025.
  • Its Net Margin stands at 21.24% for Q3 2025, versus 19.84% for Q2 2025 and 24.66% for Q1 2025.